News

Merck cooperates with Symphogen
Enlarge image

BusinessGermanyDenmark

Merck cooperates with Symphogen

07.09.2012 - German Merck KGaA enters a license deal worth up to €495m with Danish Symphogen to receive exclusive rights to a Phase II cancer drug

Symphogen's Sym004 is a recombinant IgG1 antibody product consisting of two antibodies targeting the epidermal growth factor receptor (EGFR). It is currently being evaluated in a Phase I/II trial for the treatment of patients with advanced KRAS wild-type metastatic colorectal cancer (mCRC) as a second-line treatment. In addition, a single-arm, open-label Phase II trial is on-going in patients with squamous cell carcinoma of the head and neck (SCCHN) who have failed anti-EGFR-based therapy.

Under the terms of the agreement, Merck will pay Symphogen €20m upfront. The Danish antibody specialist is also eligible to receive up to €225m for clinical development and regulatory milestones, €250m in potential combined sales performance milestones as well as royalties on net worldwide sales. In exchange, Merck will gain exclusive worldwide rights to develop and commercialise Sym004. 

Sym004 is designed to block ligand binding, receptor activation and downstream signalling. The antibodies are also thought to elicit removal of the EGFR receptors from the cancer cell surface by inducing EGFR internalisation and degradation. Merck says it sees the program as a natural extension of its Erbitux franchise.

The German pharma giant has come under pressure lately, as important R&D projects, like the oral MS treatment Cladribine, failed. In the wake of the setbacks, it decided to start a major restructuring programme. Merck decided to close down its Merck Serono headquarter in Geneva and lately announced to lay off 1,100 employees in Germany.

http://www.european-biotechnology-news.com/news/news/2012-03/merck-cooperates-with-symphogen.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

BusinessSwedenFrance

02.06.2015 After disappointing Phase III results for immunotherapy tasquinimod and the subsequent discontinuation of the prostrate cancer drug, Swedish Active Biotech is now severely downsizing its operations.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

EPOSwitzerland

30.05.2015 Pharma giant Roche has out-licensed its anaemia drug Mircera to fellow Swiss healthcare company Galenica.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • NEOVACS (F)1.25 EUR15.74%
  • SCANCELL HOLDINGS (UK)38.25 GBP14.18%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-53.97%
  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • HYBRIGENICS (F)1.86 EUR44.2%
  • GALAPAGOS (B)51.13 EUR36.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-56.7%
  • CYTOS (CH)0.61 CHF-39.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.35 EUR517.6%
  • WILEX (D)4.30 EUR465.8%
  • ADOCIA (F)69.01 EUR432.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • THROMBOGENICS (B)5.32 EUR-70.2%
  • ACTIVE BIOTECH (S)10.60 SEK-68.8%

No liability assumed, Date: 01.06.2015